Review



human nsclc egfr wild type cell lines a549  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human nsclc egfr wild type cell lines a549
    a Flow cytometry histogram of the surface antigen expression of PD-L1 in human <t>NSCLC</t> cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.
    Human Nsclc Egfr Wild Type Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 31601 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nsclc+egfr+wild+type+cell+lines+a549/pmc07426958-29-0-32?v=ATCC
    Average 99 stars, based on 31601 article reviews
    human nsclc egfr wild type cell lines a549 - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "Targeting PD-L1 in non-small cell lung cancer using CAR T cells"

    Article Title: Targeting PD-L1 in non-small cell lung cancer using CAR T cells

    Journal: Oncogenesis

    doi: 10.1038/s41389-020-00257-z

    a Flow cytometry histogram of the surface antigen expression of PD-L1 in human NSCLC cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.
    Figure Legend Snippet: a Flow cytometry histogram of the surface antigen expression of PD-L1 in human NSCLC cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.

    Techniques Used: Flow Cytometry, Expressing, Activity Assay, Co-Culture Assay, Enzyme-linked Immunosorbent Assay

    a Experimental design of the tumor xenograft model infused with PD-L1-CAR or CD19-CAR T cells. b .NSG mice were inoculated with 1.0 × 10 6 H1975-Fluc cells and infused intravenously with 5 × 10 6 PD-L1-CAR T cells or CD19-CAR T cells twice on day 7 and 0 ( n = 5 mice per group). Bioluminescence imaging was used to assess tumor growth on day 7, 14, and 28 post tumor cell inoculation. c Bioluminescence kinetics of H1975-Fluc ( n = 5 mice per group). d The percentage of PD-L1-positive cells within tumors. All cells were extracted from tumors of each treatment group on day 28 after inoculation and the expression of PD-L1 was evaluated by flow cytometry. e Representative IHC images of CD19-CAR or PD-L1-CAR T cell-treated NSCLC tumors for PD-L1 and Ki67. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors or organs on day 28. Scale bars, 200 µm. **** p ≤ 0.0001.
    Figure Legend Snippet: a Experimental design of the tumor xenograft model infused with PD-L1-CAR or CD19-CAR T cells. b .NSG mice were inoculated with 1.0 × 10 6 H1975-Fluc cells and infused intravenously with 5 × 10 6 PD-L1-CAR T cells or CD19-CAR T cells twice on day 7 and 0 ( n = 5 mice per group). Bioluminescence imaging was used to assess tumor growth on day 7, 14, and 28 post tumor cell inoculation. c Bioluminescence kinetics of H1975-Fluc ( n = 5 mice per group). d The percentage of PD-L1-positive cells within tumors. All cells were extracted from tumors of each treatment group on day 28 after inoculation and the expression of PD-L1 was evaluated by flow cytometry. e Representative IHC images of CD19-CAR or PD-L1-CAR T cell-treated NSCLC tumors for PD-L1 and Ki67. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors or organs on day 28. Scale bars, 200 µm. **** p ≤ 0.0001.

    Techniques Used: Imaging, Expressing, Flow Cytometry, Staining

    a Signal intensities of PD-L1 expression in cell lines treated with 5 Gy radiation as analyzed by flow cytometry. b Percentage of PD-L1-positive cells and cell viability in A549 cells treated with different doses of radiation for 24 or 48 h. c The effect of radiation treatment on anti-tumor efficacy of PD-L1-CAR T cells at different effector (E): target (T) ratios. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns not significant.
    Figure Legend Snippet: a Signal intensities of PD-L1 expression in cell lines treated with 5 Gy radiation as analyzed by flow cytometry. b Percentage of PD-L1-positive cells and cell viability in A549 cells treated with different doses of radiation for 24 or 48 h. c The effect of radiation treatment on anti-tumor efficacy of PD-L1-CAR T cells at different effector (E): target (T) ratios. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns not significant.

    Techniques Used: Expressing, Flow Cytometry

    a Experimental design of tumor cell xenograft model treated with CAR T cells and/or irradiation. b Serial bioluminescence imaging of tumor progression and regression in each group ( n = 3 mice per group). c Bioluminescence kinetics of A549-Fluc ( n = 3 mice per group) in each treatment group. d Representative IHC of PD-L1 in irradiation-treated NSCLC tumors. Scale bars, 100 µm. e Representative images of CD3 IHC in PD-L1-CAR T cell-treated and irradiation-treated NSCLC tumors. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors. Scale bars, 50 µm. * p ≤ 0.05.
    Figure Legend Snippet: a Experimental design of tumor cell xenograft model treated with CAR T cells and/or irradiation. b Serial bioluminescence imaging of tumor progression and regression in each group ( n = 3 mice per group). c Bioluminescence kinetics of A549-Fluc ( n = 3 mice per group) in each treatment group. d Representative IHC of PD-L1 in irradiation-treated NSCLC tumors. Scale bars, 100 µm. e Representative images of CD3 IHC in PD-L1-CAR T cell-treated and irradiation-treated NSCLC tumors. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors. Scale bars, 50 µm. * p ≤ 0.05.

    Techniques Used: Irradiation, Imaging, Staining



    Similar Products

    human nsclc egfr wild type cell lines a549  (ATCC)
    99
    ATCC human nsclc egfr wild type cell lines a549
    a Flow cytometry histogram of the surface antigen expression of PD-L1 in human <t>NSCLC</t> cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.
    Human Nsclc Egfr Wild Type Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nsclc+egfr+wild+type+cell+lines+a549/pmc07426958-29-0-32?v=ATCC
    Average 99 stars, based on 1 article reviews
    human nsclc egfr wild type cell lines a549 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    a Flow cytometry histogram of the surface antigen expression of PD-L1 in human NSCLC cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.

    Journal: Oncogenesis

    Article Title: Targeting PD-L1 in non-small cell lung cancer using CAR T cells

    doi: 10.1038/s41389-020-00257-z

    Figure Lengend Snippet: a Flow cytometry histogram of the surface antigen expression of PD-L1 in human NSCLC cell lines and BEAS-2B. b Cytotoxic activity of PD-L1-CAR T cells after 4 and 20 h of co-culture with human NSCLC cell lines and BEAS-2B. PD-L1-CAR T cells and CD19-CAR T cells were used as effector cells at various ratios of effector (E): target (T). c Secretion of cytokines analyzed by ELISA in supernatants obtained after a 20-h co-culture of effector and target cells at a 2:1 E:T ratio. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. **** p ≤ 0.0001.

    Article Snippet: Human NSCLC EGFR- wild type cell lines A549 and H1299, EGFR -mutant cell lines HCC827 (del E746-A750) and H1975 (L858R and T790M), and normal bronchial epithelial cell line (BEAS-2B) were purchased from ATCC (Manassas, VA).

    Techniques: Flow Cytometry, Expressing, Activity Assay, Co-Culture Assay, Enzyme-linked Immunosorbent Assay

    a Experimental design of the tumor xenograft model infused with PD-L1-CAR or CD19-CAR T cells. b .NSG mice were inoculated with 1.0 × 10 6 H1975-Fluc cells and infused intravenously with 5 × 10 6 PD-L1-CAR T cells or CD19-CAR T cells twice on day 7 and 0 ( n = 5 mice per group). Bioluminescence imaging was used to assess tumor growth on day 7, 14, and 28 post tumor cell inoculation. c Bioluminescence kinetics of H1975-Fluc ( n = 5 mice per group). d The percentage of PD-L1-positive cells within tumors. All cells were extracted from tumors of each treatment group on day 28 after inoculation and the expression of PD-L1 was evaluated by flow cytometry. e Representative IHC images of CD19-CAR or PD-L1-CAR T cell-treated NSCLC tumors for PD-L1 and Ki67. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors or organs on day 28. Scale bars, 200 µm. **** p ≤ 0.0001.

    Journal: Oncogenesis

    Article Title: Targeting PD-L1 in non-small cell lung cancer using CAR T cells

    doi: 10.1038/s41389-020-00257-z

    Figure Lengend Snippet: a Experimental design of the tumor xenograft model infused with PD-L1-CAR or CD19-CAR T cells. b .NSG mice were inoculated with 1.0 × 10 6 H1975-Fluc cells and infused intravenously with 5 × 10 6 PD-L1-CAR T cells or CD19-CAR T cells twice on day 7 and 0 ( n = 5 mice per group). Bioluminescence imaging was used to assess tumor growth on day 7, 14, and 28 post tumor cell inoculation. c Bioluminescence kinetics of H1975-Fluc ( n = 5 mice per group). d The percentage of PD-L1-positive cells within tumors. All cells were extracted from tumors of each treatment group on day 28 after inoculation and the expression of PD-L1 was evaluated by flow cytometry. e Representative IHC images of CD19-CAR or PD-L1-CAR T cell-treated NSCLC tumors for PD-L1 and Ki67. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors or organs on day 28. Scale bars, 200 µm. **** p ≤ 0.0001.

    Article Snippet: Human NSCLC EGFR- wild type cell lines A549 and H1299, EGFR -mutant cell lines HCC827 (del E746-A750) and H1975 (L858R and T790M), and normal bronchial epithelial cell line (BEAS-2B) were purchased from ATCC (Manassas, VA).

    Techniques: Imaging, Expressing, Flow Cytometry, Staining

    a Signal intensities of PD-L1 expression in cell lines treated with 5 Gy radiation as analyzed by flow cytometry. b Percentage of PD-L1-positive cells and cell viability in A549 cells treated with different doses of radiation for 24 or 48 h. c The effect of radiation treatment on anti-tumor efficacy of PD-L1-CAR T cells at different effector (E): target (T) ratios. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns not significant.

    Journal: Oncogenesis

    Article Title: Targeting PD-L1 in non-small cell lung cancer using CAR T cells

    doi: 10.1038/s41389-020-00257-z

    Figure Lengend Snippet: a Signal intensities of PD-L1 expression in cell lines treated with 5 Gy radiation as analyzed by flow cytometry. b Percentage of PD-L1-positive cells and cell viability in A549 cells treated with different doses of radiation for 24 or 48 h. c The effect of radiation treatment on anti-tumor efficacy of PD-L1-CAR T cells at different effector (E): target (T) ratios. Data represented technical triplicates using T cells from one donor and were shown as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns not significant.

    Article Snippet: Human NSCLC EGFR- wild type cell lines A549 and H1299, EGFR -mutant cell lines HCC827 (del E746-A750) and H1975 (L858R and T790M), and normal bronchial epithelial cell line (BEAS-2B) were purchased from ATCC (Manassas, VA).

    Techniques: Expressing, Flow Cytometry

    a Experimental design of tumor cell xenograft model treated with CAR T cells and/or irradiation. b Serial bioluminescence imaging of tumor progression and regression in each group ( n = 3 mice per group). c Bioluminescence kinetics of A549-Fluc ( n = 3 mice per group) in each treatment group. d Representative IHC of PD-L1 in irradiation-treated NSCLC tumors. Scale bars, 100 µm. e Representative images of CD3 IHC in PD-L1-CAR T cell-treated and irradiation-treated NSCLC tumors. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors. Scale bars, 50 µm. * p ≤ 0.05.

    Journal: Oncogenesis

    Article Title: Targeting PD-L1 in non-small cell lung cancer using CAR T cells

    doi: 10.1038/s41389-020-00257-z

    Figure Lengend Snippet: a Experimental design of tumor cell xenograft model treated with CAR T cells and/or irradiation. b Serial bioluminescence imaging of tumor progression and regression in each group ( n = 3 mice per group). c Bioluminescence kinetics of A549-Fluc ( n = 3 mice per group) in each treatment group. d Representative IHC of PD-L1 in irradiation-treated NSCLC tumors. Scale bars, 100 µm. e Representative images of CD3 IHC in PD-L1-CAR T cell-treated and irradiation-treated NSCLC tumors. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors. Scale bars, 50 µm. * p ≤ 0.05.

    Article Snippet: Human NSCLC EGFR- wild type cell lines A549 and H1299, EGFR -mutant cell lines HCC827 (del E746-A750) and H1975 (L858R and T790M), and normal bronchial epithelial cell line (BEAS-2B) were purchased from ATCC (Manassas, VA).

    Techniques: Irradiation, Imaging, Staining